The English philosopher Thomas Hobbes is perhaps best known for describing life in its natural state as “nasty, brutish, and short.” The same description could be applied to post-pandemic style investing.
When the market first bottomed in the spring of 2020, the initial rally was driven by technology and growth companies. Later, in the fall of 2020, investors abruptly pivoted to value stocks as news of effective vaccines favored cheap cyclicals poised to benefit from an economic recovery.
And this tug-of-war between growth and value has continued, with frequent reversals, for the past two years. Most recently, growth has come back into vogue. Since the start of the year, U.S. large cap growth stocks have gained roughly 11%, more than twice the gains for value stocks (see Chart 1).
Equity performance - year to date

Source: Refinitiv Datastream and MSCI, chart by BlackRock Investment Institute. Jun 06, 2022
Notes: The line shows the relative performance of the MSCI World Value Index versus the MSCI World Growth index. An increase in the index level means value is outperforming growth. The index is rebased to 100.
Where to next? While a slower economy and a less hostile rate environment favor growth, the value differential still tilts toward value. My take: Split the difference and stick with growth at a reasonable price, i.e., GARP.
Macro vs valuations
Slower economic growth puts a premium on growth companies. An average of economic expectations by Bloomberg suggests real U.S. GDP growth of approximately 0.5% in 2023. Back in February of 2022, the consensus was 2.5 %. While the U.S. is likely to avoid a recession, the lagged impact of monetary tightening, higher inflation and fading stimulus still suggests an economic slowdown. As I’ve discussed in previous blogs, slower economic growth puts a premium on companies able to generate organic earnings growth.
Peak rates would remove a growth headwind. Growth stocks, particularly ‘early’ growth names with no near-term earnings prospects, were disproportionately hit by last year’s surge in interest rates. While rates can climb from here, inflation is decelerating, and the Federal Reserve is nearing the end of its tightening cycle. Going forward, interest rates are likely to prove less of a headwind for growth stocks.
Growth valuations remain elevated. Using a simple ratio of price-to-earnings, U.S. large cap growth stocks trade at approximately a 70% premium to their value cousins. This ratio is well below the late 2020 peak of 105%, but still meaningfully above the long-term average of 45%. Last year’s meltdown negated growth’s ‘pandemic premium’ but growth valuations remain elevated, at least when compared to value.
Growth at a reasonable price
For investors looking to reconcile a favorable growth backdrop with less than compelling valuations, one solution is ‘growth at a reasonable price’ or GARP. I have advocated for this style before. GARP tends to be an effective ‘all-weather’ tilt. More importantly for today’s environment, GARP has historically performed particularly well when the economy is slowing but not contracting. GARP may also provide some protection against the nasty consequences of being on the wrong side of the post-pandemic growth/value divide.

The Morningstar RatingTM for funds, or "star rating," is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.